Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R (2022) Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 34:969-977.e2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kudo M (2020) Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer 9:640–662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391:1163–1173

Article  CAS  PubMed  Google Scholar 

Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer 48:1452–1465

Article  CAS  PubMed  Google Scholar 

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66

Article  CAS  PubMed  Google Scholar 

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54–63

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:282–296

Article  CAS  PubMed  Google Scholar 

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY et al (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862–873

Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M et al (2021) Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): An open-label, randomised, phase 3 trial. Lancet Oncol 22:991–1001

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380

Article  PubMed  Google Scholar 

European Association for the Study of the Liver (2018) Electronic address: easloffice.eu, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236

Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H et al (2019) Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49:1109–1113

Article  PubMed  Google Scholar 

Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H et al (2021) Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10:181–223

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B (2021) Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 75:960–974

Article  CAS  PubMed  Google Scholar 

Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S et al (2022) Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res 52:269–280

Article  CAS  PubMed  Google Scholar 

Ochi H, Kurosaki M, Joko K, Mashiba T, Tamaki N, Tsuchiya K, Marusawa H et al (2022) Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Hepatol Res 53:61–71

Article  PubMed  Google Scholar 

Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, Moriyama E et al (2022) Association between adverse events and prognosis in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A multicenter retrospective study. Cancers (Basel) 14:4284

Article  CAS  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458

Article  CAS  PubMed  Google Scholar 

Hayakawa Y, Tsuchiya K, Kurosaki M, Yasui Y, Kaneko S, Tanaka Y, Ishido S et al (2022) Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Invest New Drugs 40:392–402

Article  CAS  PubMed  Google Scholar 

Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M et al (2022) Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res 52:773–783

Article  CAS  PubMed  Google Scholar 

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M et al (2022) Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med 11:3796–3808

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S et al (2021) Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. Cancers (Basel) 13:3958

Article  CAS  PubMed  Google Scholar 

Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, Lui RN et al (2020) Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med 9:7052–7061

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yokohama K, Asai A, Matsui M, Okamoto N, Yasuoka H, Nishikawa T, Ohama H et al (2020) Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Sci Rep 10:14470

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N et al (2022) Immune-related liver injury is a poor prognostic factor in patients with nonsmall cell lung cancer treated with immune checkpoint Inhibitors. Cancer Investig 40:189–198

Article  CAS  Google Scholar 

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

Article  CAS  PubMed  Google Scholar 

Karachaliou N, Saloustros E, Vamvakas L, Mavroudis D, Georgoulias V (2010) Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. Ann Oncol 21:1729–1730

Article  CAS  PubMed  Google Scholar 

Khoja L, Kumaran G, Zee YK, Murukesh N, Swindell R, Saunders MP, Clamp AR et al (2014) Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol 48:430–434

Article  CAS  PubMed  Google Scholar 

Carvalho B, Lopes RG, Linhares P, Costa A, Caeiro C, Fernandes AC, Tavares N et al (2020) Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients. J Neurooncol 147:109–116

Article  CAS  PubMed  Google Scholar 

Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y (2013) Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Res 33:309–316

CAS  PubMed  Google Scholar 

Uysal M, Bozcuk H, Sezgin Göksu S, Murat Tatli A, Arslan D, Gündüz S, Senol Coskun H et al (2014) Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother 68:409–412

Article  CAS  PubMed  Google Scholar 

Ando Y, Kawaoka T, Kosaka M, Shirane Y,Johira Y, Miura R et al (2022) Risk factors for early onset of proteinuria in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Liver Cancer. https://doi.org/10.1159/000528145